Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Recipharm Acquires Cobra Biomanufacturing

By Drug Discovery Trends Editor | February 22, 2010

Recipharm AB has just announced the acquisition of Cobra Biomanufacturing plc, which are being combined with the existing Biologics activities located in Sweden. The integrated business will be known as RecipharmCobra Biologics and will operate as Recipharm’s  specialist biologics division.
 
The combination of both companies capabilities creates a comprehensive biological service offering, encompassing cell line development, analytical and process development and GMP production of recombinant proteins, DNA, viruses and cell products for Phase I, II and III clinical trials. This, together with fill-finish and formulation capabilities, provides customers with a true one stop shop concept for their biologics outsourcing needs.
 
Simon Saxby, former CEO of Cobra Biomanufacturing, will head up RecipharmCobra Biologics in the newly formed position of Vice President, Biologics.

With the integration complete, RecipharmCobra Biologics will have cGMP approved production facilities in Keele and Oxford, UK and Södertälje, Sweden.

RecipharmCobra Biologics holds significant IP and licences in expression technologies, including ORT-VAC and UCOE, platform expression technologies that deliver cost effective production of customer materials.         

Thomas Eldered, CEO of Recipharm AB commented: “Integrating the experience of Cobra Biomanufacturing’s staff, expertise and established services with our own previous offering has, we believe, created a much stronger force in the industry’s biologics outsourcing sector. Indeed, in addition to antibodies and rProteins, our integrated company competitively offers both process development and cGMP manufacturing services for viruses, DNA and cells.”

He added: “The move will also serve to further build our position as a leading Contract Development and Manufacturing Organisation that provides a full range of high quality services.”

Date: February 22, 2010
Source: Recipharm Biologics


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE